ETOP IBCSG Partners Foundation
The Bern-based foundation that unites the International Breast Cancer Study Group (SOFT, TEXT, POSITIVE) and the European Thoracic Oncology Platform.
The International Breast Cancer Study Group began in 1977 as the Ludwig Breast Cancer Study Group and has run academic breast cancer trials for almost fifty years, including SOFT and TEXT (ovarian function suppression in premenopausal women), the POSITIVE study of pausing endocrine therapy to attempt pregnancy, and the early HER2-positive and elderly trials. ETOP was founded in 2009 to run academic thoracic oncology trials across Europe, including BEAT-meso in mesothelioma and the SPLENDOUR and ETOP Lungscape biomarker programmes. In 2022 the two merged into the ETOP IBCSG Partners Foundation, sharing a coordinating centre in Bern and a statistical centre. Both arms partner with the Breast International Group, Breast Cancer Trials and the US cooperative groups.
- SOFT / TEXT (IBCSG 24-02, 25-02)
- POSITIVE (pregnancy after endocrine therapy)
- BEAT-meso and thoracic trials (ETOP)
- Lungscape biomarker cohort
Pages like this
not linked directly; found by shared links- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares Alliance for Clinical Trials in Oncology, Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer.
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares SOFT & TEXT, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonFabrice Barlesi
Shares Intergroupe Francophone de Cancérologie Thoracique, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- ProductExemestane
Shares SOFT & TEXT, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- InstitutionGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaUse residual disease tests to decide who needs ten years of hormone therapy
Shares SOFT & TEXT, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TermEpithelioid vs sarcomatoid (biphasic) mesothelioma
Shares BEAT-meso (ETOP 13-18), Mesothelioma.
- InstitutionInstitut Jules Bordet
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.